15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 19 firms covering AbbVie Inc, 16 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $235.00 to $300.00, so the covering firms are broadly aligned. The average target of $272.50 sits 3% above the current $263.45. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 15 to 16 over recent months. On the fundamentals, the Street sees revenue growth near 10% this year and 8% next, consensus EPS building from about $3.84 next quarter toward $16.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS19 ratings
Strong Buy
Strong Buy00%
Buy1684%
Hold316%
Sell00%
Strong Sell00%
Based on 19 analysts giving stock ratings to AbbVie Inc.
As of Jul, 16 of 19 firms rate ABBV a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABBV EPS & revenue forecast
EPS · NEXT QUARTER
$3.84
Range $3.67 – $4.08 · 17 analysts · +106% YoY
Next period, 17 analysts expect AbbVie Inc to earn $3.84 a share (range $3.67 – $4.08), versus $1.86 a year earlier. Full-year consensus is $14.12, growing to $16.27 the year after.
REVENUE · NEXT QUARTER
$17.3B
Range $16.7B – $17.5B · 17 analysts · +10% YoY
Revenue is expected to reach $17.3B (range $16.7B – $17.5B), +10.0% year-over-year. Full-year consensus is $67.3B, rising to $72.8B next year.
Top analysts covering AbbVie Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABBV.
#1
David Amsellem
Piper Sandler · Rank #95
Buy
$298.00+13.1% to target
Overall win rate
50%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #136
Buy
$276.00+4.8% to target
Overall win rate
46%
+ Follow
#3
GN
Gary Nachman
Canaccord Genuity
Buy
$282.00+7.0% to target
Coverage
—
+ Follow
#4
Geoff Meacham
Citigroup
Hold
$260.00-1.3% to target
Coverage
—
+ Follow
#5
Michael Yee
UBS
Hold
$260.00-1.3% to target
Coverage
—
+ Follow
ABBV stock forecast FAQ
What is ABBV's average 12-month price target?+
The 16 analysts with a live target average $272.50 for AbbVie Inc over the next 12 months, ranging from a $300.00 high to a $235.00 low.
Is ABBV stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 19 analyst ratings, 16 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ABBV?+
The Street-high target is $300.00 (BMO Capital), and the Street-low is $235.00 (Evercore ISI Group). The average of all 16 active targets is $272.50.
How many Wall Street analysts cover ABBV?+
19 analysts have an active rating on AbbVie Inc, and 16 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABBV?+
Among analysts who currently cover ABBV, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #95). Their current call is Buy with a $298.00 target.
What is AbbVie Inc's projected EPS for next quarter?+
The consensus estimate is $3.84 per share (range $3.67 – $4.08) across 17 analysts. Full-year EPS is projected at $14.12, rising to $16.27 the following year.
How much revenue is AbbVie Inc expected to report next quarter?+
Consensus revenue is $17.3B (range $16.7B – $17.5B). Full-year revenue is projected at $67.3B, growing to $72.8B next year.
Have analysts been upgrading or downgrading ABBV lately?+
As of Jul, 16 of 19 firms rate ABBV a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABBV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
